Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04347876 |
Recruitment Status : Unknown
Verified April 2020 by Aliae AR Mohamed Hussein, Assiut University.
Recruitment status was: Recruiting
First Posted : April 15, 2020
Last Update Posted : April 15, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
COVID-19 BCG Vaccination | Diagnostic Test: Tuberculin test |
Study Type : | Observational |
Estimated Enrollment : | 100 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Outcome of COVID-19 Cases Admitted to Hospital and ICU With Positive Tuberculin Test: Can Previous BCG Alter the Prognosis? |
Actual Study Start Date : | April 11, 2020 |
Estimated Primary Completion Date : | June 16, 2020 |
Estimated Study Completion Date : | June 30, 2020 |

Group/Cohort | Intervention/treatment |
---|---|
Group A
COVID-19 positive with positive tuberculin test
|
Diagnostic Test: Tuberculin test
Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination |
Group B
COVID-19 positive with negative tuberculin test
|
Diagnostic Test: Tuberculin test
Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination |
- Pneumonia severity index [ Time Frame: 2 weeks ]severity of COVID-19 pneumonia
- Need for ICU admission [ Time Frame: 2 weeks ]severe pneumonia indicating invasive or non invasive mechanical ventilation
- COVID -19 test conversion [ Time Frame: 2 weeks ]number of days to cure from COVID-19 disease
- Mortality [ Time Frame: 2 weeks ]frequency of fatalities

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years to 80 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- COVID-19 positive cases admitted to hospitals in Upper Egypt
Exclusion Criteria:
- None

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04347876
Egypt | |
AssiutU | Recruiting |
Assiut, Egypt, 71111 | |
Contact: Aliae AR Mohamed-Hussein +201222302352 aliaehussein@gmail.com |
Responsible Party: | Aliae AR Mohamed Hussein, Professor of Pulmonology, Assiut University |
ClinicalTrials.gov Identifier: | NCT04347876 |
Other Study ID Numbers: |
AssiutU12 |
First Posted: | April 15, 2020 Key Record Dates |
Last Update Posted: | April 15, 2020 |
Last Verified: | April 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Outcome COVID-19 pneumonia BCG Tuberculin test positive Egypt |
COVID-19 Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases |
Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |